China Pharma Holdings Total Revenue

China Pharma Holdings (CPHI) currently reports a total revenue of $5.9T as of March 2026. That compares with $3.2T in the prior-year period — up 86.1% year over year. That is above the Healthcare sector average of $110B. Use the charts on this page to explore China Pharma Holdings's total revenue history and peer comparisons.

China Pharma Holdings's total revenue increased from $3.2T to $5.9T — a 86.1% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

China Pharma Holdings's total revenue of $5.9T is higher than the Healthcare sector average of $110B. That is roughly 5467.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

China Pharma Holdings reported $5.9T in total revenue as of March 2026. That compares with $3.2T in the prior-year period — up 86.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $5.9T, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for China Pharma Holdings, and consider following CPHI for alerts when major investors trade the stock.